Enhancement of Acute Myocardial Lesions by Asthma Drugs in Rats

Abstract

Asthma morbidity and mortality have risen significantly in the last 10 years. The reasons for the increase are multifactorial. One proposed explanation is possible myocardial toxicity arising from the use of β-agonists alone or in combination with methylxanthines. Previous studies have shown that β-agonists given alone and β-agonist/methylxanthine combinations given at higher than recommended clinical doses induced dose-related cardiotoxicity and sudden death in rats. The objective of the present study was to determine whether or not β-agonists given alone and in combination with methylxanthines at recommended clinical doses also induce cardiotoxicity and sudden death in rats. The β-agonists, isoproterenol hydrochloride (15 μg/kg), fenoterol hydrobromide (40 μg/kg), and terbutaline hemisulfate (0.4 mg/kg) were given in single sc doses separately and concurrently with the methylxanthines aminophylline hydrate (20 mg/kg) and caffeine (40 mg/kg), which were given ip to a susceptible animal model, the heavy Sprague-Dawley rat. β-agonist-induced myocardial toxicity (necrosis) was observed. The toxicity was enhanced by aminophylline resulting in the sudden death (most likely due to ventricular fibrillation) of some animals. A decrease in serum iron levels was observed in rats of all β-agonist and/or methylxanthine-treated groups.

Keywords

β-agonists methylxanthines heavy rats myocardial necrosis serum ions

References

1. Balazs T (1986). Cardiotoxicity mechanisms from the point of view of preclinical or premarketing safety evaluation. Arch. Toxicol. (suppl. 9): 171–177.

2. Boline DR and Schrenk WG (1977). Atomic absorption spectroscopy of copper and iron plant material. J. Assoc. Off. Anal. Chem. 60: 1170–1174.

3. Bosco LA , Knapp DE , Gerstman B , and Graham CF (1987). Asthma drug therapy trends in the United States, 1972–1985. J. Allergy Clin. Immunol. 80: 398–402.

4. Crane J , Burgess C , and Beasley R (1989). Cardiovascular and hypokalemic effects of inhaled salbutamol, fenoterol and isoprenaline. Thorax 44: 136–140.

5. DeBoer DA and Clark RE (1992). Iron chelation in myocardial preservation after ischemia-reperfusion injury: The importance of pretreatment and toxicity. Ann. Thorac. Surg. 53: 412–418.

6. Flaherty JT and Zweier JL (1991). Role of oxygen radicals in myocardial reperfusion injury: Experimental and clinical evidence. Klin. Wochenschr. 69: 1061–1065.

7. Galietti F , Giorgis GE , Miravalle C , Oliaro A , Ardizzi A , and Barberis S (1988). Arrhythmias during combined procaterol-aminophylline treatment. Pan. Med. 30: 173–176.

8. Gerstman BB , Bosco LA , Tomita DK , Gross TP , and Shaw MM (1989). Prevalence and treatment of asthma in the Michigan medicaid patient population younger than 45 years, 1980–1986. J. Allergy Clin. Immunol. 83: 1032–1039.

9. Homcy CJ (1991). The β-adrenergic signaling pathway in the heart. Hosp. Pract. 26: 43–50.

10.

10. Institute of Laboratory Animal Resources (1985). Guide for the Care and Use of Laboratory Animals, rev. NIH Publication No. 86–23. National Research Council.

11.

11. Jenkins MA , Hurley SF , Bowes G , and McNeil JJ (1990). Use of antiasthmatic drugs in Australia. Med. J. Aust. 153: 323–328.

12.

12. Jenne JW and Tashkin DP (1992). Beta adrenergic agonists. In: Bronchial Asthma, EB Weiss and M Stein (eds). Little, Brown and Company, Boston, pp. 700–748.

13.

13. Joseph X , Whitehurst VE , Bloom S , and Balazs T (1981). Enhancement of cardiotoxic effects of β-adrenergic bronchodilators by aminophylline in experimental animals. Fund. Appl. Toxicol. 1: 443–447.

14.

14. Lehman AJ (1975). Appraisal of safety of chemicals in foods, drugs and cosmetics. In: Appraisal of Safety of Chemicals in Foods, Drugs and Cosmetics. Washington, D.C.: Department of Health, Education and Welfare, pp. 1–3.

15.

15. Lehr D (1981). Studies on the cardiotoxicity of alpha and beta adrenergic amines. In: Cardiac Toxicity, T Balazs (ed). CRC Press, Boca Raton, Florida, pp. 75–112.

16.

16. Lofdahl C-G and Barnes PJ (1986). Calcium, calcium channel blockade and airway function. Acta Pharmacol. Toxicol. 58: 91–111.

17.

17. Mitchell EA (1989). Is current treatment increasing mortality and morbidity? Thorax 44: 81–84.

18.

18. Novey HS (1983). Cardiotoxicity of combined theophylline-beta adrenergic agonist therapy for asthma. Immunol. Allergy Pract. 7: 208–211.

19.

19. Persson CGA (1984). The pharmacology of antiasthmatic xanthines and adenosine. In: Asthma Reviews, I Morely (ed). Academic Press, New York, pp. 115–129.

20.

20. Raymond JR , Hnatowich M , Lefkowitz RJ , and Caron MG (1990). Adrenergic receptors–-Models for regulation of signal transduction processes. Hypertension 15: 119–131.

21.

21. Robin ED and McCauley R (1992). Sudden cardiac deaths in bronchial asthma, and inhaled beta-adrenergic agonists. Chest 101: 1699–1702.

22.

22. Sears MR , Rea HH , Rothwell RPG , O'Donnell TV , Holst PE , Gillies AJD , and Beaglehole R (1986). Asthma mortality: Comparison between New Zealand and England. Br. Med. J. 293: 1342–1345.

23.

23. Skikne BS (1987). A commercial electrochemical method for measurement of iron status. Clin. Chem. 33: 1645–1647.

24.

24. Sly MR , Chairman, The American Academy of Allergy and Immunology Committee on Drugs (1985). Adverse effects and complications of treatment with beta-adrenergic agonist drugs. J. Allergy Clin. Immunol. 75: 443–449.

25.

25. Stiles GL (1990). Adenosine receptors and beyond: Molecular mechanisms of physiological regulation. Clin. Res. 38: 10–18.

26.

26. Whitehurst VE , Joseph X , Hohmann JR , Pledger G , and Balazs T (1983). Cardiotoxic effects in rats and rabbits treated with terbutaline alone and in combination with aminophylline. J. Am. Coll. Toxicol. 2: 147–153.

27.

27. Wong CS , Pavord ID , Williams J , Britton JR , and Tattersfield AE (1990). Bronchodilator, cardiovascular and hypokalemic effects of fenoterol, salbutamol and terbutaline in asthma. Lancet 336: 1396–1399.